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Abstract
Hepatitis C virus (HCV) genotypes 4, 5 and 6 represent 420% of all HCV
cases worldwide. HCV-4 is mainly seen in Egypt, where it represents 90% of all
HCV cases. Antischistosomal therapy was the main cause of contamination
there, followed by procedures performed by informal providers and tradi-
tional healers such as dental care, wound treatment, circumcision, deliveries,
excision and scarification. It is also highly prevalent in sub-Saharan Africa and
in the Middle East. In Europe, its prevalence has recently increased particularly
among intravenous drug users and in immigrants. HCV-5 is mainly found in
South Africa, where it represents 40% of all HCV genotypes, but four pockets
of HCV-5 were found in France, Spain, Syria and Belgium and sporadic cases
were found elsewhere. The mode of transmission is mainly iatrogenic and
transfusion. HCV-6 is found in Hong Kong, Vietnam, Thailand and Myanmar
and also in American and Australian from Asian origin. The response to
treatment in HCV-4 is intermediate between HCV-1 and HCV-2 and HCV-3.
A sustained viral response is achieved in 43–70% with pegylated interferon
and ribavirin. It is higher in Egyptians than Europeans and Africans and is
negatively related to insulin resistance and to the severity of fibrosis. It
increases to 4 80% with 24 weeks of therapy only if a rapid virological
response is achieved. In HCV-5, a sustained virological response is achieved in
4 60% with 48 weeks of therapy. HCV-6 is also considered an easy-to-treat
genotype, leading to a response in 60–85% of cases.
Six main hepatitis C virus (HCV) genotypes, called types
1–6, numerous ‘subtypes’ (1) as well as a recently
identified seventh type (Innogenetics, unpublished data)
have been identified by the phylogenetic analysis of
partial or full-length sequences of HCV isolates from
different regions of the world. Variants isolated princi-
pally in South East Asia were found to be divergent
between types and subtypes (2–4). They were incorpo-
rated into their phylogenetically closest type (all type 6,
except for one type 3 strain) (1).
The distribution of HCV genotypes reflects the epide-
miology of hepatitis C and as such is also strongly
associated with particular routes of transmission (5).
Genotype is one of the determinants of the response to
antiviral combination therapy with interferon (IFN)-a
and ribavirin. HCV genotyping is currently performed
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before initiating therapy to tailor its duration and the
frequency of monitoring in the individual patient.
Genotypes 1 (HCV-1), followed by genotypes 2 (HCV-
2) and 3 (HCV-3), are the most common genotypes in
North and South America and Europe (6), and have been
the focus of most clinical trials. Genotype 4 (HCV-4) is
the most frequent cause of chronic hepatitis C in the
Middle-East, North Africa and sub-Saharan Africa. It has
recently spread to southern Europe, particularly among
intravenous drug users (IVDUs) and in immigrants (7).
Genotype 5 (HCV-5) was initially reported in South
Africa, where it represents 40% of all cases (8, 9), and
recent reports have confirmed its presence in some other
countries. Genotype 6 (HCV-6) is rare and confined to
South East Asia (10–13), Asian Americans and Asian
Australians. Although they represent 420% of all HCV
cases worldwide, genotypes 4, 5 and 6 have generally been
neglected in clinical trials.
The aim of this Consensus Document, drafted by a
working party established by the World Gastroenterology
Organization in 2007, is to review 2009 current knowl-
edge on the prevalence, epidemiology, natural history
and treatment outcome of HCV genotype 4, 5 and 6
infections, based on published and sometimes unpub-
lished data and on expert opinions, in order to elaborate
consensual recommendations because clinical trials of
therapy for these genotypes are unlikely.
Global distribution of the ‘rare’ hepatitis C virus
genotypes
Hepatitis C virus-4 is mainly found in Egypt, the country
with the highest prevalence of HCV worldwide (415%),
where it represents 90% of all HCV cases (14). It only
represents 5–11% of cases in the other North African
countries. It is also highly prevalent in sub-Saharan
Africa and in the Middle East, with a proportion ranging
from 36 to 100% of all HCV cases. In Europe, its
prevalence is low, but an increased prevalence has re-
cently been noted in France, Italy and Belgium. HCV-4 is
very rare in North, Central and South America and
almost nonexistent in other parts of the world (Table 1).
Until recently, it was thought that HCV-5 was confined
to South Africa, where it represents 40% of all HCV
genotypes. However, four pockets of HCV-5 have been
found in France, Spain, Syria and Belgium (Table 2) and
sporadic cases have been found elsewhere in the world.
Hepatitis C virus-6 is mainly found in Hong Kong,
Vietnam, Thailand, Myanmar (Burma) and in Asian
Americans and Asian Australians (Table 3).
Table 1. Proportion of hepatitis C virus-4 in hepatitis C virus patients worldwide
Area Countries HCV-4 (%) Countries HCV-4 (%)
North Africa Egypt (14) 90 Tunisia (15) 11
Sudan (15) 5
Sub-Saharan Africa Congo (15) 100 Gabon (15) 97
Cameroon (15) 36 Rwanda (15) 100
Liberia (15) 100 Uganda (15) 100
Middle East Syria (16) 59 KSA (17) 62
Iraq (18) 35.4 Iran (19) 0.9
Jordan (20) 26.6 (dialysis) Lebanon (21) 45.7–36.5
Asia China (11) 0–1.7
North America USA (22, 23) 0–2 Canada (24) 2.3–3.9
Central and South America Argentina (25) 0.5–4.6 Brazil (26) 0.1–0.67
Mexico (27) 1
Europe France (28) 4–10 Greece (29, 30) 3–15.2
Spain (29, 31) 1.4–19 Turkey (29, 32) 0–2.2
Portugal (29) 0 Italy (29, 33, 34) 0–2.2
UK (unpublished) 6.7 Belgium (35) 10
Austria (36) 5 the Netherlands (37) 10
Germany (38) 1–2
Table 2. Proportion of hepatitis C virus-5 in hepatitis C virus patients
worldwide
Area Countries HCV-5 (%)
Africa South Africa (8, 9, 39) 40
Middle East Syria (16) 10
Europe France (28, 40) 3
Belgium (41) 1–5
UK 0.7
Spain (42) 0–10.3
Italy (43) 0–0.1
America Canada (24) 0.1–4.5
Table 3. Proportion of hepatitis C virus-6 in hepatitis C virus patients
worldwide
Area Countries HCV-6 (%)
Asia China (10, 44) 0
China IVDU (45, 46) 46–50
Thailand (47) 18.7
Hong Kong (10–12) 10–30
Vietnam (48) 14
Asian in the US and Canada USA (49, 50) 11
Canada (24) 0.3–0.8
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Epidemiology
Hepatitis C virus-4
The risk factors for HCV-4 transmission are determined
by the geographical distribution of this genotype.
The epidemiology of hepatitis C virus-4 in Egypt and in
sub-Saharan Africa
Antischistosomal therapy has been the main cause of
contamination in Egypt. In fact, epidemiological and
molecular evolutionary studies in Egypt relate the origin
of the HCV-4 epidemic to the mass antischistosomal
campaign, which was administered parenterally, and only
stopped in the mid-1960s (51, 52). However, the inci-
dence of HCV remains high even after the treatment
campaign was stopped and new infections continue to
occur in young individuals who did not receive parent-
eral antischistosomal therapy. Blood transfusion was a
major route for HCV-4 transmission before obligatory
HCV screening in blood banks in 1994. Currently, the
major route of transmission appears to be health-related
procedures with inadequately sterilized instruments and
supplies. Procedures performed by non-medical profes-
sionals and traditional healers such as dental care, wound
treatment, circumcision, deliveries, excision and scarifi-
cation have all been identified as important risk factors
for HCV transmission in Egypt (53–56). Occupational
transmission among healthcare workers through needle
sticks and injuries from sharp objects contributes to new
HCV cases because needle stick-prevention devices have
not yet been adopted by most hospitals and healthcare
units. Inadequate compliance to universal, standard
precautions in some health facilities also remains an issue
(57–59). Low prevalence rates of IVDU are reported in
Egypt. However, IVDU accounts for a significant percen-
tage of HCV-4 cases when the source is unknown (60). It
has been suggested that high rates of sexual transmission
are a probable mode of transmission based on seropre-
valence data, although phylogenetic analysis has only
been performed in one study (61). In rural Egypt, sexual
transmission between monogamous spouses (62) ranged
between 3 and 34% (95% CI 0–49). However, the extent
of sexual transmission of HCV-4 could not be estimated
because of the presence of other confounding variables
such as IVDU or shared items among sexual partners.
In Sudan, Zaire, Gabon, Central African Republic,
Cameroon and Kenya (63–67), scarification, circumci-
sion practices and sexual transmission may contribute to
the persistence and propagation of HCV transmission.
The marked genetic diversity and many subtypes identi-
fied suggest that HCV-4 has been endemic and propagat-
ing in sub-Saharan Africa for a long time (68).
Epidemiology of hepatitis C virus-4 in Europe
Hepatitis C virus-4 has recently spread to several Eur-
opean countries, especially those on the Mediterranean
such as Italy, France, Greece and Spain. Ten to 24% of
HCV are genotype 4 in these countries (28, 30, 42, 43,
69). HCV-4 infections are frequent among IVDUs (Eur-
opean and non-European), HCV/HIV-coinfected pa-
tients and immigrants from North and sub-Saharan
Africa (37, 38, 70–72). HCV-4 was probably introduced
into Europe through immigration and the movement of
IVDUs across European borders.
In Greece, a study in 277 patients with HCV-4 showed
that 15% had been contaminated by organ transplanta-
tion, 19% were IVDUs, 23% had received transfusions,
4% had haemophilia while the cause was unknown in
39% (73). In Italy, a study in 339 patients with HCV-4
showed that 11.8% were IVDUs, 1.7% received blood
transfusion and the cause of contamination was un-
known in 86.5% (74). In Spain, a study of 855 patients
with HCV-4 showed that the cause of contamination was
IVDU in 37.1% and unknown in 62% (34).
In France, four studies have assessed the epidemiology of
HCV-4 (28, 75–77). They showed an increasing prevalence
of HCV-4 representing 9% of all HCV patients. HCV-4 was
more common in patients o40 years old and was more
frequently found among IVDUs (28). Roulot and collea-
gues study (76) included 1532HCV-4 patients from 19 liver
departments (69% French, 15% Egyptians and 16% Afri-
cans). It confirmed the heterogeneity of HCV-4 according
to the patients’ geographical origin. The patients in the
African group were older than those in the French and
Egyptian groups (50 11, 44 10 and 45 10 years,
respectively, P  0.001). The route of transmission was
predominantly related to IVDU in patients in the French
group (56%), a history of antischistosomal therapy in the
Egyptian group (62%) and a history of blood transfusion in
the African group (21%). Egyptians were mainly infected
with subtype 4a (93%), French with 4a (54%) or 4d (33%),
while Africans were infected with diverse subtypes.
In Belgium, the prevalence of HCV-4 has also signifi-
cantly increased, accounting for about 10% of the cases of
chronic hepatitis C in 2002 (32). European patients har-
bouring HCV-4 in Belgium either had a history of IVDU
and were mainly infected with the subtype 4c/4d, or were
non-IVDU and showed a huge diversity of subtypes (70).
Epidemiology of hepatitis C virus-4 in the Americas,
South East Asia and Australia
Hepatitis C virus-4 infections are infrequent in the US
(24, 49, 78). Most HCV-4 infections are found in
immigrants from endemic countries, individuals who
acquired the infection overseas or IVDUs. There are no
reliable data on the prevalence of HCV-4 either in
Australia or in South East Asia. However, HCV-4 appears
to be rare in these regions.
Hepatitis C virus-5
For many years, HCV-5 was believed to be confined to
the northern part of South Africa, where it accounts for
up to 40% of HCV-infected patients. But it has now also
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been reported in other parts of the world including
France, Belgium, Canada, Syria, Spain and Brazil (16,
42, 79–83). Recent investigations indicate that there are
three pockets of HCV-5 infection outside South Africa:
the West-Flanders region of Belgium, the central area of
France around Clermont-Ferrand and the northern part
of Syria.
An analysis of diversity based on the sequence com-
parison of a 470 bp fragment of the NS3-NS4B region
encoding for non-structural proteins was performed
comparing South African and Belgian strains. The phy-
logenetic study assessing viral evolutionary history
showed that geographically distinct clusters have been
evolving independently for a considerable period of time
(4120 years) between South African and Belgian strains.
It was originally thought that HCV-5 originated in South
Africa. But, recently, it has been speculated that HCV-5
may have originated in Central Africa and spread
through human migration associated with trade in a
north–south direction (41). A case–control study and
phylogenetic analysis were performed in Central France
(84). This study included 131 HCV-5-infected patients.
Results showed that all but two HCV-5 patients were
Caucasian. HCV-5 contamination was associated with
transfusion and unsafe injections performed before 1972
by the local physician. In Syria, HCV-5 represents 10% of
all HCV genotypes and is almost exclusively found in the
north of Syria in the province of Aleppo, with half of the
cases originating from Azaz, a small city of 30 000
inhabitants close to the Turkish border. But no cases of
HCV-5 have ever been reported in Turkey or any other
countries neighbouring Syria and there is no immigra-
tion from Africa to Syria (16). However, a recent phylo-
genetic analysis of Syrian samples showed that the Syrian
samples are clustered in the South African group (un-
published data).
The route of transmission is thought to be mainly
blood transfusion in South Africa, iatrogenic and
transfusion in France and unknown for the most part in
Belgium, Syria and Spain.
Hepatitis C virus-6
Data on regional epidemiology and on risk factors of
HCV-6 are lacking. Unsafe therapeutic injections, IVDU
and blood transfusion are the probable modes of trans-
mission of HCV-6.
Natural history
Hepatitis C virus-4
Few well-designed studies have investigated the natural
history of HCV-4 partly because of the difficulty of
conducting long-term studies over decades in well-
characterized untreated cohorts. Although a possible
relationship has been suggested between HCV genotype
and disease progression, no such relationship has ever
been validated (85). There are few data on the natural
history of HCV-4 in western Europe in relation to the
acute form of the disease and its progression towards
chronic hepatitis. Similarly, there are few data on the
progression of fibrosis to cirrhosis and hepatocellular
carcinoma (HCC).
Prospective studies have shown that the overall rates of
spontaneous resolution in acute HCV-4 infections range
from 20 to 50% (86, 87). However, patients with acute
HCV-4 and HIVor Schistosoma mansoni coinfection have
lower rates of spontaneous viral clearance (86, 88).
The rate of progression of fibrosis in HCV-4 mono-
infection (0.1 0.06 fibrosis units per year) is not
significantly different from the rates reported in genotype
1, 2 or 3 (88). Patients with HCV-4 and schistosomiasis
coinfection have higher fibrosis scores. Coinfected pa-
tients show accelerated rates of fibrosis, reaching
0.61 0.13 fibrosis unit within 8–12 years (88–91). Two
French studies have evaluated the severity of the disease
and the predictors of advanced fibrosis in HCV-4
patients (76, 77). The first retrospective study included a
large number of HCV-4 patients from 19 French liver
centres, with available liver biopsies in 1205 patients (802
French, 198 Egyptians and 205 Africans). At diagnosis,
severe histological activity (Metavir score A2–A3) was
present in 39% of patients and was significantly more
frequent in the Egyptian group than that in the French
and African groups (51.3 vs. 36.9 and 35.8%,
Po 0.0007) (76). Similarly, the proportion of patients
with cirrhosis (13.5%, on average) was higher in the
Egyptian than that in the French and African groups
(29.8 vs. 10.8 and 8.3%, Po 0.001). However, multi-
variate analysis was not performed in this study to
determine the independent predictors of cirrhosis. In
the second prospective study including 226 consecutive
HCV-4 patients (Egyptians 40%, Europeans 35% and
Africans 24%), the predictors (logistic regression) of
severe fibrosis (Metavir score F3–F4) were assessed
according to epidemiological, metabolic and virological
factors. The results of this study showed that severe
fibrosis was independently associated with Egyptian
origin (Po 0.001), excessive alcohol intake (P= 0.021)
and insulin resistance (Po 0.001) (77). Moreover, a
subgroup analysis based on the geographical origin of
patients was performed because severe fibrosis was most
frequent in Egyptians (may be secondary to the longer
duration of infection), and it was found that insulin
resistance remained a major predictor of severe fibrosis in
both groups (Egyptians and non-Egyptians). It should
also be noted that HOMA-IR correlated directly with
serum HCV-RNA levels in this study, confirming pre-
vious results (71) and suggesting a direct role of the virus
in the development of insulin resistance.
A possible association between HCV-4 and the high
rates of HCC in Egypt has been suggested based on the
similarity of distribution of HCC and HCV-4. More than
65% of HCC cases in Egypt are anti-HCV positive.
Currently, liver cancer constitutes 13% of all cancers in
Egypt and is now considered the second most frequent
Liver International (2009)
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cancer in men, and more frequent among rural residents
and farmers (92), when it was fourth in 1999 (93). One
study showed a significant association not only with
subtype 4a but also with subtype 4o (94). However, care
should be taken not to overinterpret any potential
relationship between HCV-4 and HCC based on epide-
miological data, while other factors related to HCC such
as extensive use of pesticides and prevalence of aflatoxins
have not been taken into account (95).
Hepatitis C virus-5
Limited data are available on the natural history of
genotype 5.
A large multicentre multinational South African data-
base of 285 patients has been compiled (S. W. van der
Merwe, unpublished data). The mean age of these
patients was 59 years, and 54% were females. Eighty-
three per cent of infections were thought to have been
contracted through blood transfusions. Baseline alanine
aminotransferase was normal in 52% and cirrhosis was
already present in 26% at first presentation. The baseline
viral load was recently assessed in a viral kinetic study;
the mean HCV-RNAwas 6.33 0.28 (log10 IU/ml) in the
HCV-5 cohort, 6.23 0.66 in the HCV-1 cohort and
6.15 0.85 in the HCV-2/3 cohort. These values were
comparable to those of large historical cohorts of geno-
types 1, 2 and 3 (96).
In a French study, viral characteristics were studied in
26 patients infected with genotype 5. The mean age was
57 years, 58% of the patients were women, the mean
pretreatment viral load was 5.97 logU/ml, 50% of the
patients were infected by blood transfusion and cirrhosis
was present in 35% of the individuals (79).
Finally, in a Syrian study, data from 64 HCV-5 patients
also showed that most patients were women (61%), with
a mean age of 52 years, significantly older than non-
genotype 5 patients (Po 0.0001). The cause of transmis-
sion was only known in 30%, blood transfusion being
reported in 14% of the patients. Cirrhosis was present in
23% of the patients (16).
In conclusion, all available data showed that more
women are infected with HCV-5, with a mean age that is
older than non-genotype 5 patients. Viral load is usually
high and cirrhosis is frequently found at diagnosis.
Hepatitis C virus-6
In the only study of the natural history of HCV-6 in 80
Hong Kong Chinese patients (97), no differences were
found between HCV-1 and HCV-6 patients in baseline
liver biochemistry, HCV-RNA titres, cumulative risk
of development of cirrhotic complications and HCC,
even when patients were stratified according to age and
gender.
Treatment
Hepatitis C virus-4
A few clinical trials have been performed in acute HCV-4
and have demonstrated high sustained virological re-
sponse (SVR) rates with IFN-based therapies compared
Table 4. Therapy of human immunodeficiency virus/hepatitis C virus-4 coinfected patients and therapy of acute hepatitis C virus-4
References Study design
Number of
patients Treatment
Duration of
treatment
(weeks) SVR (%)
Legrand-Abravanel
et al. (100)
A case–control study of patients with
HCV-4 in France; 13 of 28 were HIV
coinfected
28 PEG-IFN-a-2b 1.5 mcg/kg/
week1RBV 1000–1200 mg/
dayw
48 15
Soriano et al. (101) A retrospective analysis of open-label
clinical trials in HCV-4 patients with
HCV and HIV coinfectionz
42 IFN-a-3 MU three times a week
(n= 9)
48 11.1
IFN-a-3 MU three times a week
plus RBV 800 mg/day (n= 11)
9.1
PEG-IFN-a-2b 1.5 mcg/week
plus RBV 800 mg/day (n= 22)
22.7
Martı´n-Carbonero
et al. (102)
A retrospective analysis of clinical trials
in HCV-4 patients with HCV and HIV
coinfection in Italian and Spanish
studies.
75 PEG-IFN-a-2b and a-2a 48 28
Kamal et al. (98) Randomized controlled trial of Egyptian
patients with acute HCV-4
53 PEG-IFN-a-2b monotherapy 12 84
Kamal et al. (99) Randomized controlled trial of Egyptian
patients with acute HCV-4
40 PEG-IFN-a-2b monotherapy 8 77
12 93
24 100
Adapted with permission from Kamal and Nasser (15) and Kamal (120).
SVR was defined as undetectable HCV RNA at the end of a 24-week follow-up period.
wRBV was administered according to a weight-based administration schedule.
zPatients were allocated to treatment groups according to personal financial ability to afford treatment.
PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response.
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with no treatment. SVR was achieved in 60 and 88% of
genotype 1 patients and in 93 and 100% of HCV-4
patients after 12 and 24 weeks of pegylated interferon
(PEG-IFN) monotherapy respectively (98, 99) (Table 4).
Early reports on the treatment of chronic HCV-4 with
IFN monotherapy showed disappointing SVR rates ran-
ging between 5 and 25% (103, 104). Addition of ribavirin
improved SVR rates to 25–42%, which were similar to
SVR in HCV genotype 1 patients but much lower than
HCV-2 and HCV-3 patients (105–108). It was then
concluded that HCV-4, like HCV-1, was a ‘difficult-to-
treat’ genotype even with PEG-IFN and thus early studies
from the western countries reported response to treat-
ment of HCV-1 and HCV-4 together. However, studies
from Egypt, France and other countries in the Middle
East have shown that treatment of chronic HCV-4 with
PEG-IFN and ribavirin was associated with better rates of
SVR ranging from 43 to 70% (76, 108–118). But studies
from Egypt showed a higher SVR than SVR from
European studies. This was intriguing until the publica-
tion of two French studies, which evaluated SVR in
monoinfected HCV-4 patients treated with PEG-IFN
and ribavirin in different groups (76, 77). In the first
retrospective study, which include 242 HCV-4-treated
patients (55% French, 30% Egyptians and 15% Africans),
the overall rate of SVR was 43.4%. The SVR rates were
significantly higher in the Egyptian group than in the
French and African groups: 54.9 vs. 40.3 and 32.4%
respectively. By univariate analyses, SVR was also asso-
ciated with age o 45 years, HCV-4 subtype 4a, low
serumHCV-RNA levels and mild fibrosis. In multivariate
analysis, two factors were independently associated with
SVR: an Egyptian origin and the absence of severe
fibrosis. The second study was prospective and included
108 consecutive HCV-4-treated patients (48% Egyptians,
30% Europeans and 21% Africans), the overall SVR rate
was 54%, but the SVR rates were significantly different
according to the geographical origin of the patients:
Egyptians (63%) vs. Europeans (51%) vs. Africans
(39%). Besides geographical origin (Po 0.001), SVR
was independently associated with HOMA-IRo 2
(P= 0.001) and non-severe fibrosis (Po 0.001). More-
over, HOMA-IR remained a major predictor of SVR
when Egyptians and non-Egyptians were analysed sepa-
rately. It is interesting to note that 80 patients (74%)
achieved an early virological response (EVR) in this
study, defined as aZ2 log10 decline in serum HCV-RNA
levels from baseline (partial EVR) or undetectable HCV-
RNA in serum (complete EVR) at treatment week 12. An
EVR had a good positive predictive value (PPV= 72%)
and an excellent negative predictive value (NPV= 96%)
of SVR (Tables 5 and 6).
Defining the optimal treatment duration ensures suc-
cessful long-term treatment outcomes with the shortest
possible treatment duration to reduce cost and maximize
tolerance (120). In a double-blind, randomized study
conducted to determine the optimum treatment dura-
tion for patients with HCV-4 (112), patients received
PEG-IFN-a-2b and ribavirin according to a weight-based
administration schedule for 24, 36 or 48 weeks. In
this study, SVRs were significantly higher in patients
receiving treatment for 36 or 48 weeks (66 and 69%
respectively) than in those in the 24-week regimen (29%)
(P= 0.001). In addition, for the group of patients
who have achieved a complete EVR, the SVR rate was
86% with 36 weeks of therapy and 92% with 48 weeks
of therapy (P= 0.8) Although the frequency and type of
general adverse events were similar in each group,
PEG-IFN dose reductions were significantly more com-
mon in patients receiving 48 weeks of therapy than in
those receiving 24 or 36 weeks of therapy (Po 0.05).
Rapid virological response (RVR), defined as unde-
tectable serum HCV-RNA levels at week 4 of therapy, has
been a useful tool for determining the duration of PEG-
IFN and ribavirin therapy for HCV-1 (121). Two studies
(72, 115) have shown that 24 weeks of therapy induce an
SVR in chronic HCV-4 patients achieving RVR. The first
study (115) demonstrated that patients with RVR and
EVR assigned to PEG-IFN-a-2b and ribavirin therapy for
24 and 36 weeks, respectively, had high SVR rates (86 and
76% respectively), with significantly fewer adverse events
and better compliance than those treated for 48 weeks.
After controlling for predictors, low baseline histological
activity grade and fibrosis stage were associated with SVR
(Po 0.029) in all groups.
The second study was a prospective study conducted in
13 centres and including 516 chronic HCV patients (geno-
type 1, n= 450; genotype 4, n= 66) treated with PEG-IFN
plus ribavirin (72). Patients with HCV-4 more frequently
had an RVR than those with genotype 1 (45 vs. 26%) in that
study. Moreover, 86% of HCV-4 patients with RVR
achieved an SVR after 24 weeks of treatment compared with
78% of HCV-1 patients with RVR and the same duration of
treatment. Interestingly, the SVR rate was not influenced in
HCV-4 patients with RVR (unlike HCV-1 patients) by the
level of serum HCV-RNA or the stage of liver fibrosis.
Recently, the combination of nitazoxanide, PEG-
IFN-a-2a and ribavirin increased the percentages of pa-
tients achieving an RVR and SVR, compared with patients
receiving only PEG-IFN plus ribavirin (SVR 79 and 50%
respectively) with no increase in adverse events (119).
Few trials have addressed treatment outcome in HCV/
HIV-coinfected patients. In one report, the overall SVR
was 11.1% in patients receiving IFN-a monotherapy,
9.1% in patients receiving IFN-a plus ribavirin combination
therapy and 22.7% in patients receiving PEG-IFN-a-2b
(1.5 mg/week) plus ribavirin (800mg/day) (101). In an-
other study, end of treatment response and SVR rates
were lower in HIV/HCV-coinfected patients than that in
HCV-monoinfected patients (30 vs. 66%, P= 0.06; 15 vs.
50%, P= 0.06 respectively) receiving PEG-IFN-a plus
ribavirin (1000–1200mg/day) for 48 weeks (100). A
recent Italian Spanish study assessed the efficacy of
PEG-IFN and ribavirin therapy in 75 HCV-4 patients
coinfected with HIV. The overall SVR was 28% in an
intention-to-treat analysis (102).
Liver International (2009)
c 2009 John Wiley & Sons A/S 347
Antaki et al. HCV genotypes 4, 5 and 6
Table 5. Summary of randomized control trials and studies with control groups of pegylated interferon-a in patients with hepatitis C virus-4
References Study design
Number
of patients Treatment
Duration of
treatment
(weeks) SVR (%)
Kamal et al. (112) Prospective, double-blind,
randomized study of Egyptian
patients with HCV-4
260 PEG-IFN-a-2b 1.5 mcg/kg/week1
RBV 1000–1200 mg/dayw for 24
weeks (n= 95)
24 29
PEG-IFN-a-2b 1.5 mcg/kg/week1
RBV 1000–1200 mg/dayw for 36
weeks (n= 96)
36 66z
PEG-IFN-a-2b 1.5 mcg/kg/week1
RBV 1000–1200 mg/dayw for 48
weeks (n= 69)
48 69z
Alfaleh et al. (109) Randomized, parallel-group study
of Saudi patients with HCV
59 PEG-IFN-a-2b 100 mcg/week plus
RBV 800 mg/day (n= 28)‰
48 42.9
IFN-a-2b 3 MU three times a week
plus RBV 800 mg/day (n= 31)‰
48 32.3
Derbala et al. (114) Randomized controlled study of
patients in Qatar with HCV-4 and
a history of bilharziasis
73 PEG-IFN-a-2a 180 mcg/week1RBV
1200 mg/day for (n= 38)
48 65.8z
IFN-a-2b 3 MU three times a week
plus RBV 1200 mg/day (n= 35)
48 25.7
Kamal et al. (115) Prospective, treatment duration
based on virological response at
week 4 or 12 in Egyptian patients
with chronic HCV-4
308 PEG-IFN-a-2b 1.5 mcg/kg/week1
RBV 1000–1200 mg/dayw for
according to virological response
at weeks 4 or 12 respectively
24 86 (RVR)
36 76 (complete
EVR)
48 58 (partial
EVR)
Esmat et al. (105) Prospective, open-label
randomized study of Egyptian
patients with chronic HCV-4
PEG-IFN-a-2b 100 mcg/week plus
RBV 800–1000 mg/day
48 55
IFN-a-2b 2 MU three times a week
plus RBV 800–1000 mg/day
40
Ferenci et al. (72) Prospective trial investigating
response-guided therapy.
66 PEG-a-2a (180mg/week plus ribavirin
1000 or 1200 mg/day according to
virological response at weeks 4
24 (if RVR) 87
48
72
Rossignol et al. (119) Prospective trial 96 PEG-IFN-2a and ribavirin for 48
weeks, n= 40), nitazoxanide
monotherapy for 12 weeks followed
by nitazoxanide plus PEG-IFN-2a for
36 weeks (n= 28), or nitazoxanide
monotherapy for 12 weeks followed
by nitazoxanide plus peginterferon-
a-2a and ribavirin for 36 weeks
(n= 28). Therapeutics included
nitazoxanide (500 mg) twice daily,
peginterferon-a-2a (180mg) once
weekly, and weight-based ribavirin
(1000–1200 mg/day).
48 50
Triple therapy: PEG-IFN plus
ribavirin plus nitazoxanide
36 61
36 79
Moucari et al. (77) Prospective study on Egyptian,
European African patients
108 PEG-IFN-a-2a 62% 48 Egyptians:
63%
PEG-IFN-a-2b 38% Europeans:
51%
Africans:
39%
Adapted with permission from Kamal and Nasser (15) and Kamal (120).
SVR was defined as undetectable HCV RNA at the end of a 24-week follow-up period.
wRBV was administered according to a weight-based administration schedule.
zP= 0.001 vs. 24-week treatment regimen.
‰Data presented for HCV-4 patients only.
zPo 0.05 vs. conventional IFN.
PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response.
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Hepatitis C virus-5
There are no prospective studies on the treatment of
HCV-5. Only five non-randomized retrospective studies
have been performed reporting treatment response rates
for HCV-5 including a limited number of patients.
D’Heygere (122) reported a 48% SVR in 21 patients. In
a study on 26 Syrian patients, Antaki et al. (123) reported
an overall SVR of 54% in patients treated either with IFN
(17 patients, SVR 47%) or PEG-IFN (nine patients, SVR
66.6%). A similar SVR rate was found in patients treated
for 24 weeks (13 patients, SVR 54%) or 48 weeks (13
patients, SVR 54%) in this study. Finally, Bonny et al.
(80) showed an overall SVR rate of 60% (52/87), which
was not different according to the type of treatment (IFN
vs. PEG-IFN). In patients who received PEG-IFN, an
EVR was achieved in 98% of patients. In the same study,
107 patients with HCV-1 and 51 patients with HCV-2
and HCV-3 treated with PEG-IFN plus ribavirin were
compared with the 27 HCV-5 patients treated with the
same regimen in one of the participating centres. Even
though HCV-5 patients were older, had more severe liver
fibrosis and more frequently had higher levels of viraemia
than HCV-2/3 patients, the SVR rates were similar in
both groups (60 vs. 63%, P= 0.8098) and significantly
higher than that in HCV-1 patients (37%, P= 0.0499).
The low success rate in the D’Heygere study is
probably related to the inclusion of prior relapsers.
Because of the limited number of patients included, the
retrospective nature of the studies reported and the lack
of evidence from controlled-randomized clinical trials,
the ideal treatment duration cannot be determined.
However, overall, the different studies have shown that
the response to treatment in genotype 5, like genotype
4, is intermediate between genotype 1 and genotypes 2
and 3 and the SVR varies between 55 and 87%. In
Table 6. Summary of non-randomized control trials, retrospective and post hoc studies of pegylated interferon-a in patients with hepatitis C
virus-4
References Study design
Number
of patients Treatment
Duration of
treatment
(weeks) SVR (%)
El-Zayadi et al.
(113)
Non-randomized study of
patients in Egypt with HCV-4w
180 PEG-IFN-a-2b 100 mcg/week1RBV
1000–1200 mg/day (n= 40)z
48 55.0‰
PEG-IFN-a-2b 100 mcg/week1RBV
1000–1200 mg/day (n= 70)
24 48.6z
IFN-a-2b 3 MUk1RBV
1000–1200 mg/day1AMD 200 mg/
day (n= 70)
24 28.6
Hasan et al. (107) Open-label, prospective study of
treatment-naive HCV-4 patients
in Kuwait
66 PEG-IFN-a-2b 1.5 mcg/kg/
week1RBV 1000–1200 mg/dayz
48 68
Roulot et al. (76) A retrospective non-randomized
study French, Egyptian and
African patients with chronic
HCV-4
242 PEG-IFN-a-2b 1.5 mcg/kg/
week1RBV 1000–1200 mg/dayz
48 Egyptians: 54.9
French: 40.3
Africans: 32.4
Diago et al. (108) Post hoc analysis of patients
with HCV-4 from two large,
double-blind clinical trials
98 Study 1: PEG-IFN-a-2a 180 mcg/
week1RBV 1000–1200 mg/dayz
(n= 13)
48 79
Study 2: PEG-IFN-a-2a 180 mcg/
week1RBV 800–1200 mg/dayz for
24 or 48 weeks
48 63
High-dose RBV (n= 24) 48 67
Low-dose RBV (n= 8) 24 0
High-dose RBV (n= 12) 24
Low-dose RBV (n= 5)
Trapero-Marugan
et al. (118)
Open-label study of Spanish
patients with chronic HCV-4
29 IFN-a-2b 3 MU three times/week
plus RBV 800–1000 mg/day (n= 19)
48 55
Peg-IFN-a-2b (1.5mg/kg/week) plus
ribavirin (1–1.2 g/day) (n= 10)
Adapted with permission from Kamal and Nasser (15) and Kamal (120).
SVR was defined as undetectable HCV RNA at the end of a 24-week follow-up period.
‰P= 0.006.
zP= 0.015 vs. induction dose regimen.
kInterferon was administered daily for the first four weeks of the study and then thrice weekly for the remaining 20 weeks.
AMD, amantadine; PEG-IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response.
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addition, the SVR was almost similar with the use of
IFN or PEG-IFN (with ribavirin). Antaki’s study also
showed a similar SVR for a treatment course of 24 or 48
weeks (Table 7).
Recently, the first viral kinetic study has been con-
ducted assessing viral kinetic parameters in non-cirrhotic
HCV-5 patients and comparing this with historical
cohorts of HCV-1, HCV-2 and HCV-3 patients (96).
The first phase viral decline in HCV-5 patients was
significantly more pronounced than that of HCV-1, and
similar to that observed for HCV-2 and HCV-3. The viral
decline pattern in all genotype 5 patients was bi-phasic,
similar to genotype 2–3 patients, and did not show a
transient rebound in HCV-RNA that occurs in some
genotype 1 patients treated with PEG-IFN-a2a. The
second phase decline slope was significantly faster for
HCV-5 (mean 1.6 log10 IU/ml/week) than HCV-1 (0.7
log10 IU/ml/week) and similar to that of HCV-2 and
HCV-3 patients (1.5 log10 IU/ml/week). These findings
in South African HCV-5 patients showed that the de-
crease of viraemia was more marked in HCV-5 than in
HCV-1 and similar to those in HCV-2 and -3, suggesting
that a shorter duration of therapy may be warranted in
HCV-5; however, the geographic variations in the treat-
ment outcome must be further evaluated.
Hepatitis C virus-6
Only six studies have been published so far comparing
the SVR rate of patients infected with HCV-1 with that of
patients infected with HCV-6. After 12 months of
combination treatment with IFN and ribavirin, Hui
reported a 62.5% SVR rate in 16 Hong Kong patients
with HCV-6 and a 29.2% SVR rate in 24 patients with
HCV-1 (124). Following combination therapy for 52
weeks with IFN and ribavirin, Dev reported an 82.5%
SVR rate in 40 Asian Australian patients with HCV-6
compared with a 61.9% SVR rate in 21 patients with
HCV-1 (13). Notably, patients in the latter study received
a daily dose of 5 million units of IFN for 8 weeks as
induction therapy, which may explain the differences in
SVR rates observed between the two studies. Fung and
colleagues analysed treatment response data after a 48-
week PEG-IFN and ribavirin regimen in 21 Hong Kong
patients with HCV-6 and in 21 patients with HCV-1.
SVR rate was 86% for patients infected with HCV-6 and
52% for those infected with HCV-1 (125). In their
retrospective study of a group of Asian American patients
infected with HCV-6, Nguyen et al. (126) analysed
the response to treatment of 66 patients. These patients
were divided into three groups: group 1 consisted of 31
patients treated by combination therapy with IFN and
ribavirin for 24 weeks, group 2 included 23 patients who
completed a 24-week combination treatment course with
PEG-IFN and ribavirin and group 3 consisted of 12
patients who completed a 48-week treatment course with
PEG-IFN and ribavirin. The SVR rate was 51.6% for
group 1, 39% for group 2 and 75% for group 3. The
difference in the SVR rate was not statistically significant
between groups 1 and 2 (P= 0.363) but was significant
between groups 2 and 3 (P= 0.044). These results in-
dicate that a higher SVR rate is obtained when treating
patients with HCV-6 with a 48-week course of PEG-IFN
and ribavirin than with a 24-week regimen. Li reported
an SVR in eight out of nine HCV-6 patients from Hong
Kong treated with PEG-IFN and ribavirin. Two of the
patients were treated for 24 weeks (127). Finally, PThi
reported the response to treatment in 75 HCV-6 Vietna-
mese patients. SVR was achieved in 69% of 42 naı¨ve
patients and in 60% of 33 non-responder patients to
previous treatment with standard IFN and ribavirin. All
patients were treated with a 48-week course of PEG-
IFN-a-2a and ribavirin. All patients who had achieved an
RVR achieved an SVR (128) (Table 8).
In conclusion, the SVR rate in HCV-6 patients treated
with a 48-week regimen of PEG-IFN and ribavirin varies
Table 7. Sustained virological response in hepatitis C virus-5
References Number of patients treated
SVR
(%)
Delwaide et al. (81) 6 83
Legrand-Abravanel et al. (79) 12 67
D’Heygere et al. (122) 21 (including relapsers) 48
Antaki et al. (123) 26 54
Bonny et al. (80) 87 60
Table 8. Sustained virological response in hepatitis C virus-6
References Number of HCV-6 patients/number of HCV-1 patients
SVR in
HCV-6 (%)
SVR in HCV-1 as a
control group (%)
Hui et al. (124) 16 (Hong Kong)/24 62.5 29.2
Dev et al. (13) 40 (Asian Australian)/21 82 61.9
Fung et al. (125) 21 (Hong Kong)/21 86 52
Nguyen et al. (126) 31 (24 weeks IFN plus ribavirin) 51
23 (24 weeks PEG-IFN plus ribavirin) 39
12 (48 weeks PEG-IFN plus ribavirin) 75
Li et al. (127) 9 89
PThi (128) 42 naı¨ve 69
33 non-responders 60
HCV, hepatitis C virus; PEG-IFN, pegylated interferon; SVR, sustained virological response.
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between 66 and 86%, which makes HCV-6 one of the so-
called ‘easy-to-treat’ genotypes (129).
Conclusion and recommendations
Hepatitis C virus genotypes 4, 5 and 6 represent 20% of
all HCV infection cases worldwide. They are spreading
outside their main foci and reaching western countries,
and so they should not be neglected by the medical
community. Although useful data and prospective stu-
dies are available for HCV-4, there are still many issues
that need to be clarified, mainly the optimal duration of
treatment. For the patients achieving an RVR, it seems
reasonable to recommend a 24-week therapy regimen.
Two studies have confirmed that patients achieving an
RVR have an 86% SVR rate (72, 115). For the patients
achieving a complete EVR and who have a low baseline
viral load and mild fibrosis, an SVR is obtained in 86%
with 36 weeks of therapy regimen compared with an SVR
of 92% for the patients with EVR treated for 48 weeks.
The difference is not statistically significant (115). Two
other issues are still debatable in HCV-4: the benefit of
adding nitazoxanide to combination therapy and the
cause of the discrepancy in response to antiviral therapy
in terms of SVR between Egyptian patients and others
infected with HCV-4: ethnicity, the different subtypes or
the insulin resistance? Prospective studies are needed in
HCV-5 and HCV-6 to determine the optimal duration of
treatment. However, HCV-5 and HCV-6 may be consid-
ered ‘easy-to-treat’ genotypes as they may have similar
SVR as HCV-2 and HCV-3 but with a longer duration of
treatment (48 vs. 24 weeks).
In conclusion, the experts’ panel would like to recom-
mend the following:
(1) HCV-4
1. If RVR is achieved, treat for 24 weeks regardless of
viral load at baseline.
2. It has been suggested in two studies that if a patient
achieves a complete EVR and if the viral load at baseline
is low and the fibrosis is mild, treatment for 36 weeks is
an acceptable option. But these data need further con-
firmation in genotype 4 and other genotypes.
3. If partial EVR, treat for 48 weeks.
(2) HCV-5
1. Treat for 48 weeks. If there is no EVR, consider
discontinuation (data are lacking for RVR and EVR).
2. Prospective study should address the role of RVR and
will determine whether and when a shorter duration is
possible.
(3) HCV-6
1. Evidence of higher SVR with 48 weeks than 24 weeks.
2. If there is no EVR, consider discontinuation (data are
lacking for RVR and EVR).
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